Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents.
The emergence of oligoclonal bands is associated with a favorable outcome after autologous stem cell transplantation in multiple myeloma. The aim of this study was to determine the prevalence of immunoglobulin oligoclonality in 33 patients with multiple myeloma in complete remission achieved with primary therapy with either cytotoxic agents (n = 18, 54.5%) or new induction regimens incorporating novel drugs (n = 15, 45.4%). Eleven patients (33.3%) developed oligoclonal bands. In the group treated with novel agents, this oligoclonal immune response was observed in 60% (9 of 15) of the patients versus only 11.1% (2 of 18) of those given cytotoxic therapy (P = 0.003). This is the first report showing a different frequency of oligoclonal humoral response in patients in complete remission achieved after conventional cytotoxic therapy versus induction incorporating novel agents. This difference could be due to a higher antitumor effect associated with the use of novel drugs, a stronger immune reconstitution, or both.
Fernández de Larrea
Carlos
C
Departments of Hematology, Servei d'Hematologia, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Tovar
Natalia
N
Cibeira
M Teresa
MT
Aróstegui
Juan I
JI
Rosiñol
Laura
L
Elena
Montserrat
M
Filella
Xavier
X
Yagüe
Jordi
J
Bladé
Joan
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D043025:Oligoclonal Bands / Q000097:blood* / Q000652:urine*; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate
D000970:Antineoplastic Agents; D043025:Oligoclonal Bands